Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Down – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) gapped down prior to trading on Friday . The stock had previously closed at $10.94, but opened at $10.50. Bayer Aktiengesellschaft shares last traded at $10.48, with a volume of 189,266 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on BAYRY shares. DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Zacks Research raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. Finally, UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The company has a debt-to-equity ratio of 1.22, a quick ratio of 0.63 and a current ratio of 1.01. The firm’s 50 day moving average is $11.25 and its 200-day moving average is $11.21. The firm has a market cap of $41.70 billion, a price-to-earnings ratio of -16.58, a price-to-earnings-growth ratio of 3.51 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. The business had revenue of $15.73 billion during the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.